DarioHealth (NASDAQ:DRIO) Stock Price Passes Below 200-Day Moving Average of $1.65

DarioHealth Corp. (NASDAQ:DRIO)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.65 and traded as low as $1.15. DarioHealth shares last traded at $1.18, with a volume of 61,199 shares changing hands.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus restated a “buy” rating and issued a $4.00 price target on shares of DarioHealth in a report on Monday, April 1st.

DarioHealth Stock Performance

The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.67 and a current ratio of 2.95. The firm has a market cap of $35.61 million, a P/E ratio of -0.71 and a beta of 1.53. The firm’s fifty day moving average price is $1.44 and its 200 day moving average price is $1.65.

DarioHealth (NASDAQ:DRIO) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.39. The business had revenue of $5.76 million during the quarter, compared to analyst estimates of $5.95 million. DarioHealth had a negative net margin of 282.38% and a negative return on equity of 76.11%. Sell-side analysts expect that DarioHealth Corp. will post -1.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Appian Way Asset Management LP grew its position in DarioHealth by 0.9% during the 1st quarter. Appian Way Asset Management LP now owns 1,334,142 shares of the company’s stock worth $2,041,000 after purchasing an additional 11,698 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of DarioHealth in the 3rd quarter valued at $3,968,000. Finally, Clarity Capital Partners LLC boosted its holdings in shares of DarioHealth by 20.1% in the 1st quarter. Clarity Capital Partners LLC now owns 204,758 shares of the company’s stock valued at $313,000 after acquiring an additional 34,332 shares during the last quarter. Institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.